Skip to main content
. 2018 Oct 17;178(1):97–103. doi: 10.1007/s00431-018-3268-x
What is Known:
Pulse oximetry is increasingly implemented as a screening tool for critical congenital heart defects in newborns.
Previous studies suggest that the screening in cost-effective and in the USA a reduction in infant mortality from critical congenital heart defects was demonstrated.
What is New:
This is the first cost-effectiveness analysis for pulse oximetry screening in a setting with screening after home births, with screening at two moments.
Costs of pulse oximetry screening in a setting with hospital and homebirth deliveries were €14.71 and is likely to be cost-effective accordint to Dutch standards.